Drugs & Therapy Perspectives

, Volume 29, Issue 11, pp 336–341

Buprenorphine/naloxone sublingual tablet (Zubsolv®): a guide to its use in the maintenance treatment of opioid dependence in the USA

Adis Drug Clinical Q&A

DOI: 10.1007/s40267-013-0079-z

Cite this article as:
Lyseng-Williamson, K.A. Drugs Ther Perspect (2013) 29: 336. doi:10.1007/s40267-013-0079-z

Abstract

Zubsolv® is a new sublingual formulation of buprenorphine/naloxone that is indicated for the maintenance treatment of opioid dependence in the USA. The effectiveness and tolerability of buprenorphine/naloxone in this indication is well established. Relative to other sublingual formulations of buprenorphine/naloxone, Zubsolv® dissolves more rapidly, has greater bioavailability, tastes better, and may be preferred by many patients.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations